tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2024 Dec;13(1):2332660.
doi: 10.1080/22221751.2024.2332660. Epub 2024 Apr 28. Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
Siyue Jia[SUP] 1 [/SUP], Zundong Yin[SUP] 2 [/SUP], Hongxing Pan[SUP] 1 [/SUP], Fuzhen Wang[SUP] 2 [/SUP], Xiaoqiang Liu[SUP] 3 [/SUP], Qing Wang[SUP] 4 [/SUP], Li Zhang[SUP] 5 [/SUP], Jihai Tang[SUP] 6 [/SUP], Hao Yang[SUP] 7 [/SUP], Jiangbo Du[SUP] 8 [/SUP], Zhiguo Wang[SUP] 1 [/SUP], Pengfei Jin[SUP] 1 [/SUP], Zhihang Peng[SUP] 8 [/SUP], Rong Tang[SUP] 1 [/SUP], Guodong Kang[SUP] 1 [/SUP], Xuewen Wang[SUP] 9 [/SUP], Simin Li[SUP] 10 [/SUP], Weixiao Wang[SUP] 8 [/SUP], Jingxin Li[SUP] 1 8 10 [/SUP], Hongbing Shen[SUP] 8 2 [/SUP], Fengcai Zhu[SUP] 1 8 10 [/SUP]
Affiliations
Effectiveness of heterologous booster regimes with ad5 vectored COVID-19 vaccine in a large, diverse population during the national-scale outbreak of SARS-CoV-2 omicron predominance in China has not been reported, yet. We conducted a large-scale cohort-control study in six provinces in China, and did a retrospective survey on the COVID-19 attack risk during this outbreak. Participant aged ≥18 years in five previous trials who were primed with 1 to 3 doses of ICV received heterologous booster with either intramuscular or orally inhaled ad5 vectored COVID-19 vaccine were included in the heterologous-trial cohort. We performed propensity score-matching at a ratio of 1:4 to match participants in the heterologous-trial cohort individually with the community individuals who received three-dose of ICV as a control (ICV-community cohort). From February 4 to April 10, 2023, 41504 (74.5%) of 55710 individuals completed the survey. The median time since the most recent vaccination to the onset of the symptoms of COVID-19 was 303.0 days (IQR 293.0-322.0). The attack rate of COVID-19 in the heterologous-trial cohort was 55.8%, while that in the ICV-community cohort was 64.6%, resulting in a relative effectiveness of 13.7% (95% CI 11.9 to 15.3). In addition, a higher relative effectiveness against COVID-19 associated outpatient visits, and admission to hospital was demonstrated, which was 25.1% (95% CI 18.9 to 30.9), and 48.9% (95% CI 27.0 to 64.2), respectively. The heterologous booster with ad5 vectored COVID-19 vaccine still offered some additional protection in preventing COVID-19 breakthrough infection versus homologous three-dose regimen with ICV, 10 months after vaccination.
Keywords: COVID-19 vaccine; Effectiveness; hazard ratio; heterologous immunization; homologous immunization.
. 2024 Dec;13(1):2332660.
doi: 10.1080/22221751.2024.2332660. Epub 2024 Apr 28. Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
Siyue Jia[SUP] 1 [/SUP], Zundong Yin[SUP] 2 [/SUP], Hongxing Pan[SUP] 1 [/SUP], Fuzhen Wang[SUP] 2 [/SUP], Xiaoqiang Liu[SUP] 3 [/SUP], Qing Wang[SUP] 4 [/SUP], Li Zhang[SUP] 5 [/SUP], Jihai Tang[SUP] 6 [/SUP], Hao Yang[SUP] 7 [/SUP], Jiangbo Du[SUP] 8 [/SUP], Zhiguo Wang[SUP] 1 [/SUP], Pengfei Jin[SUP] 1 [/SUP], Zhihang Peng[SUP] 8 [/SUP], Rong Tang[SUP] 1 [/SUP], Guodong Kang[SUP] 1 [/SUP], Xuewen Wang[SUP] 9 [/SUP], Simin Li[SUP] 10 [/SUP], Weixiao Wang[SUP] 8 [/SUP], Jingxin Li[SUP] 1 8 10 [/SUP], Hongbing Shen[SUP] 8 2 [/SUP], Fengcai Zhu[SUP] 1 8 10 [/SUP]
Affiliations
- PMID: 38678636
- DOI: 10.1080/22221751.2024.2332660
Effectiveness of heterologous booster regimes with ad5 vectored COVID-19 vaccine in a large, diverse population during the national-scale outbreak of SARS-CoV-2 omicron predominance in China has not been reported, yet. We conducted a large-scale cohort-control study in six provinces in China, and did a retrospective survey on the COVID-19 attack risk during this outbreak. Participant aged ≥18 years in five previous trials who were primed with 1 to 3 doses of ICV received heterologous booster with either intramuscular or orally inhaled ad5 vectored COVID-19 vaccine were included in the heterologous-trial cohort. We performed propensity score-matching at a ratio of 1:4 to match participants in the heterologous-trial cohort individually with the community individuals who received three-dose of ICV as a control (ICV-community cohort). From February 4 to April 10, 2023, 41504 (74.5%) of 55710 individuals completed the survey. The median time since the most recent vaccination to the onset of the symptoms of COVID-19 was 303.0 days (IQR 293.0-322.0). The attack rate of COVID-19 in the heterologous-trial cohort was 55.8%, while that in the ICV-community cohort was 64.6%, resulting in a relative effectiveness of 13.7% (95% CI 11.9 to 15.3). In addition, a higher relative effectiveness against COVID-19 associated outpatient visits, and admission to hospital was demonstrated, which was 25.1% (95% CI 18.9 to 30.9), and 48.9% (95% CI 27.0 to 64.2), respectively. The heterologous booster with ad5 vectored COVID-19 vaccine still offered some additional protection in preventing COVID-19 breakthrough infection versus homologous three-dose regimen with ICV, 10 months after vaccination.
Keywords: COVID-19 vaccine; Effectiveness; hazard ratio; heterologous immunization; homologous immunization.